Browse Category

CSL Limited News 21 November 2025 - 10 December 2025

CSL Limited (ASX:CSL) Share Price Near $180: Latest News, Analyst Forecasts and 2026 Outlook as at 10 December 2025

CSL Limited (ASX:CSL), the Melbourne‑based plasma and vaccines giant, is finishing 2025 under intense scrutiny from investors, regulators and politicians alike. As of the afternoon of 10 December 2025, CSL shares are trading around A$180–182, after closing at about A$181.82

10 December 2025

CSL Limited (ASX:CSL) Stock Outlook on 2 December 2025: Share Price Slump, Seqirus Spin-Off, New Vaccine Plant and a A$750m Buyback

Updated: 2 December 2025 CSL Limited’s share price has spent most of 2025 in the sin bin, but behind the drawdown sits a mix of solid earnings growth, a radical restructuring, a forthcoming spin‑off of its vaccines arm and fresh

2 December 2025

Corporate News · CSL Limited · Healthcare Industry · Investment Analysis · Stock Market

CSL Limited (ASX:CSL) Stock Today: Buyback Update, Share Price Action and Outlook – 27 November 2025

Sydney – Thursday, 27 November 2025 CSL Limited (ASX:CSL) enters the final month of 2025 still nursing one of the toughest years in its history. After profit downgrades, a delayed vaccine spin‑off and a brutal share-price slump, the biotech giant

27 November 2025

CSL Limited · Investment Analysis · Market Outlook · Share Buybacks · Stock Market

CSL Limited (ASX: CSL) pre‑open brief for 17 November 2025: Buy‑back in full swing, Seqirus spin‑off delayed, guidance cut — here’s what matters

CSL Share Price Update: Buy‑Back Acceleration and US$1.5 Billion US Expansion Shape Outlook on 21 November 2025

MELBOURNE / SYDNEY – 21 November 2025 – CSL Limited (ASX: CSL), the Australian biopharmaceutical giant and long‑time ASX 20 heavyweight, entered Friday’s trade with two dominant storylines: a fresh on‑market share buy‑back update lodged with the ASX this morning, and the

21 November 2025

Buybacks · CSL Limited · Expansion Plans · Market Outlook · Share Price

Go toTop